Economics of chronic hepatitis B and hepatitis C Arathi Rajendra, John B. Wong  Journal of Hepatology  Volume 47, Issue 4, Pages 608-617 (October 2007) DOI: 10.1016/j.jhep.2007.07.016 Copyright © 2007 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Cost-effectiveness plot of antiviral treatment for chronic hepatitis B [52]: This graph displays lifetime costs and quality-adjusted life years associated with single and sequential antiviral treatments for chronic hepatitis B [52]. The lines define the cost-effectiveness frontier. Any points above the line are inferior and excluded by dominance or extended dominance. The slopes of the lines equal the incremental cost-effectiveness ratio between any two strategies. Abbreviations: S, supportive care; I, Interferon; L, lamivudine; PI, peginterferon; A, adefovir. Journal of Hepatology 2007 47, 608-617DOI: (10.1016/j.jhep.2007.07.016) Copyright © 2007 European Association for the Study of the Liver Terms and Conditions